Coherus BioSciences Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Coherus BioSciences stock.
View analyst ratings for Coherus BioSciences or view top-rated stocks.

5 Wall Street research analysts have issued 1 year price targets for Coherus BioSciences' shares. Their CHRS stock forecasts range from $7.00 to $30.00. On average, they expect Coherus BioSciences' stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 162.1% from the stock's current price.
View analysts' price targets for Coherus BioSciences or view top-rated stocks among Wall Street analysts.

Coherus BioSciences' stock was trading at $15.96 at the beginning of 2022. Since then, CHRS shares have decreased by 54.6% and is now trading at $7.25.
View the best growth stocks for 2022 here.

Coherus BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Coherus BioSciences.

Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its earnings results on Thursday, May, 5th. The biotechnology company reported ($1.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by $0.44. The biotechnology company earned $60.12 million during the quarter, compared to analysts' expectations of $68.07 million. Coherus BioSciences had a negative trailing twelve-month return on equity of 211.68% and a negative net margin of 69.24%.
View Coherus BioSciences' earnings history.

21 employees have rated Coherus BioSciences CEO Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among Coherus BioSciences' employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Coherus BioSciences include Bavarian Nordic A/S (BVNRY), BioCryst Pharmaceuticals (BCRX), Twist Bioscience (TWST), Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), Krystal Biotech (KRYS), Allogene Therapeutics (ALLO), Immunocore (IMCR), ImmunityBio (IBRX), Recursion Pharmaceuticals (RXRX), Revolution Medicines (RVMD), Valneva (VALN), SpringWorks Therapeutics (SWTX), Exscientia (EXAI) and Vaxcyte (PCVX).
View all of CHRS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Coherus BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.59%), State Street Corp (6.67%), Vanguard Group Inc. (6.12%), Peregrine Capital Management LLC (1.22%), Thompson Siegel & Walmsley LLC (0.91%) and Northern Trust Corp (0.91%). Company insiders that own Coherus BioSciences stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends for Coherus BioSciences.

CHRS stock was sold by a variety of institutional investors in the last quarter, including Phocas Financial Corp., Eagle Asset Management Inc., Bank of New York Mellon Corp, Citigroup Inc., South Dakota Investment Council, UBS Group AG, Group One Trading L.P., and American Century Companies Inc.. Company insiders that have sold Coherus BioSciences company stock in the last two years include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mcdavid Stilwell, Vincent R Anicetti, and Vladimir Vexler.
View insider buying and selling activity for Coherus BioSciences or view top insider-selling stocks.

CHRS stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Peregrine Capital Management LLC, Vanguard Group Inc., BlackRock Inc., Thompson Siegel & Walmsley LLC, Renaissance Technologies LLC, Royce & Associates LP, and Sei Investments Co..
View insider buying and selling activity for Coherus BioSciences or or view top insider-buying stocks.

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHRS stock can currently be purchased for approximately $7.25.

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $561.32 million and generates $326.55 million in revenue each year. The biotechnology company earns $-287.10 million in net income (profit) each year or ($2.730010) on an earnings per share basis.

Coherus BioSciences employs 332 workers across the globe.

Coherus BioSciences was founded in 2010.

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for Coherus BioSciences is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at [email protected].